晚期卵巢癌的新辅助化疗：我们的共识与分歧是什么？ - Suppr

Neoadjuvant chemotherapy in advanced ovarian cancer: On what do we agree and disagree?

作者信息

Vergote Ignace, du Bois Andreas, Amant Frederic, Heitz Florian, Leunen Karin, Harter Philipp

机构信息

University Hospital Leuven, Leuven Cancer Institute, Division of Gynecological Oncology, Department of Obstetrics and Gynecology, Leuven, Belgium European Union.

Kliniken Essen Mitte, Department of Gynecology & Gynecologic Oncology, Essen, Germany.

出版信息

Gynecol Oncol. 2013 Jan;128(1):6-11. doi: 10.1016/j.ygyno.2012.09.013. Epub 2012 Sep 21.

DOI:10.1016/j.ygyno.2012.09.013

PMID:23006973

Abstract

摘要

相似文献

Neoadjuvant chemotherapy in advanced ovarian cancer: On what do we agree and disagree?

Gynecol Oncol. 2013 Jan;128(1):6-11. doi: 10.1016/j.ygyno.2012.09.013. Epub 2012 Sep 21.

LTE-commenting on "Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer" (90: 163-9).

Gynecol Oncol. 2004 Mar;92(3):1017-8; author reply 1018-9. doi: 10.1016/j.ygyno.2003.11.050.

Neoadjuvant chemotherapy for advanced ovarian cancer.

Gynecol Oncol. 1999 Aug;74(2):311-2. doi: 10.1006/gyno.1999.5529.

[Neoadjuvant chemotherapy for advanced ovarian cancer].

Harefuah. 2010 Jun;149(6):377-81, 402.

Cytoreduction vs. neoadjuvant chemotherapy for ovarian cancer.

Gynecol Oncol. 2008 Dec;111(3):391-9. doi: 10.1016/j.ygyno.2008.07.058.

A case of bowel perforation after neoadjuvant chemotherapy for advanced epithelial ovarian cancer.

Gynecol Oncol. 2007 Dec;107(3):586-9. doi: 10.1016/j.ygyno.2007.09.008. Epub 2007 Oct 18.

Neoadjuvant chemotherapy for advanced ovarian cancer.

Gynecol Oncol. 1994 Apr;53(1):33-7. doi: 10.1006/gyno.1994.1083.

Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival.

Gynecol Oncol. 1999 Jan;72(1):93-9. doi: 10.1006/gyno.1998.5236.

Neoadjuvant chemotherapy for ovarian cancer: clarifying the confusion.

Oncology (Williston Park). 2008 Nov 30;22(13):1456; author reply 1456-7.

Neoadjuvant chemotherapy in advanced ovarian cancer: what kind of evidence is needed to convince US gynaecological oncologists?

Gynecol Oncol. 2010 Oct;119(1):1-2. doi: 10.1016/j.ygyno.2010.08.011.

引用本文的文献

Isolated Liver Recurrence After Cytoreduction in High-Grade Serous Ovarian Carcinoma: Experience of a Tertiary Center in Turkey.

J Clin Med. 2025 Mar 7;14(6):1791. doi: 10.3390/jcm14061791.

Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options.

Drugs. 2023 Oct;83(15):1365-1385. doi: 10.1007/s40265-023-01934-0. Epub 2023 Sep 22.

Prediction of Surgical Outcome in Advanced Ovarian Cancer by Imaging and Laparoscopy: A Narrative Review.

Cancers (Basel). 2023 Mar 22;15(6):1904. doi: 10.3390/cancers15061904.

Stem cell-assisted enzyme/prodrug therapy makes drug-resistant ovarian cancer cells vulnerable to natural killer cells through upregulation of NKG2D ligands.

Med Oncol. 2023 Mar 2;40(4):110. doi: 10.1007/s12032-023-01975-1.

Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.

Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2.

Multi-Disciplinary Care Planning of Ovarian Cancer in Older Patients: General Statement-A Position Paper from SOFOG-GINECO-FRANCOGYN-SFPO.

Cancers (Basel). 2022 Mar 2;14(5):1295. doi: 10.3390/cancers14051295.

What underlies the observed hospital volume-outcome relationship?

BMC Health Serv Res. 2022 Jan 14;22(1):70. doi: 10.1186/s12913-021-07449-2.

Risk of venous thromboembolism in ovarian cancer patients receiving neoadjuvant chemotherapy.

Gynecol Oncol. 2021 Oct;163(1):36-40. doi: 10.1016/j.ygyno.2021.07.030. Epub 2021 Jul 24.

Joint IARC/NCI International Cancer Seminar Series Report: expert consensus on future directions for ovarian carcinoma research.

Carcinogenesis. 2021 Jun 21;42(6):785-793. doi: 10.1093/carcin/bgab043.

Choosing the right timing for interval debulking surgery and perioperative chemotherapy may improve the prognosis of advanced epithelial ovarian cancer: a retrospective study.

J Ovarian Res. 2021 Mar 27;14(1):49. doi: 10.1186/s13048-021-00801-4.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Neoadjuvant chemotherapy in advanced ovarian cancer: On what do we agree and disagree?

作者信息

Vergote Ignace, du Bois Andreas, Amant Frederic, Heitz Florian, Leunen Karin, Harter Philipp

机构信息

University Hospital Leuven, Leuven Cancer Institute, Division of Gynecological Oncology, Department of Obstetrics and Gynecology, Leuven, Belgium European Union.

Kliniken Essen Mitte, Department of Gynecology & Gynecologic Oncology, Essen, Germany.

出版信息

Gynecol Oncol. 2013 Jan;128(1):6-11. doi: 10.1016/j.ygyno.2012.09.013. Epub 2012 Sep 21.

DOI:10.1016/j.ygyno.2012.09.013

PMID:23006973

Abstract

摘要

相似文献

Neoadjuvant chemotherapy in advanced ovarian cancer: On what do we agree and disagree?

Gynecol Oncol. 2013 Jan;128(1):6-11. doi: 10.1016/j.ygyno.2012.09.013. Epub 2012 Sep 21.

LTE-commenting on "Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer" (90: 163-9).

Gynecol Oncol. 2004 Mar;92(3):1017-8; author reply 1018-9. doi: 10.1016/j.ygyno.2003.11.050.

Neoadjuvant chemotherapy for advanced ovarian cancer.

Gynecol Oncol. 1999 Aug;74(2):311-2. doi: 10.1006/gyno.1999.5529.

[Neoadjuvant chemotherapy for advanced ovarian cancer].

Harefuah. 2010 Jun;149(6):377-81, 402.

Cytoreduction vs. neoadjuvant chemotherapy for ovarian cancer.

Gynecol Oncol. 2008 Dec;111(3):391-9. doi: 10.1016/j.ygyno.2008.07.058.

A case of bowel perforation after neoadjuvant chemotherapy for advanced epithelial ovarian cancer.

Gynecol Oncol. 2007 Dec;107(3):586-9. doi: 10.1016/j.ygyno.2007.09.008. Epub 2007 Oct 18.

Neoadjuvant chemotherapy for advanced ovarian cancer.

Gynecol Oncol. 1994 Apr;53(1):33-7. doi: 10.1006/gyno.1994.1083.

Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival.

Gynecol Oncol. 1999 Jan;72(1):93-9. doi: 10.1006/gyno.1998.5236.

Neoadjuvant chemotherapy for ovarian cancer: clarifying the confusion.

Oncology (Williston Park). 2008 Nov 30;22(13):1456; author reply 1456-7.

Neoadjuvant chemotherapy in advanced ovarian cancer: what kind of evidence is needed to convince US gynaecological oncologists?

Gynecol Oncol. 2010 Oct;119(1):1-2. doi: 10.1016/j.ygyno.2010.08.011.

引用本文的文献

Isolated Liver Recurrence After Cytoreduction in High-Grade Serous Ovarian Carcinoma: Experience of a Tertiary Center in Turkey.

J Clin Med. 2025 Mar 7;14(6):1791. doi: 10.3390/jcm14061791.

Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options.

Drugs. 2023 Oct;83(15):1365-1385. doi: 10.1007/s40265-023-01934-0. Epub 2023 Sep 22.

Prediction of Surgical Outcome in Advanced Ovarian Cancer by Imaging and Laparoscopy: A Narrative Review.

Cancers (Basel). 2023 Mar 22;15(6):1904. doi: 10.3390/cancers15061904.

Stem cell-assisted enzyme/prodrug therapy makes drug-resistant ovarian cancer cells vulnerable to natural killer cells through upregulation of NKG2D ligands.

Med Oncol. 2023 Mar 2;40(4):110. doi: 10.1007/s12032-023-01975-1.

Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.

Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2.

Multi-Disciplinary Care Planning of Ovarian Cancer in Older Patients: General Statement-A Position Paper from SOFOG-GINECO-FRANCOGYN-SFPO.

Cancers (Basel). 2022 Mar 2;14(5):1295. doi: 10.3390/cancers14051295.

What underlies the observed hospital volume-outcome relationship?

BMC Health Serv Res. 2022 Jan 14;22(1):70. doi: 10.1186/s12913-021-07449-2.

Risk of venous thromboembolism in ovarian cancer patients receiving neoadjuvant chemotherapy.

Gynecol Oncol. 2021 Oct;163(1):36-40. doi: 10.1016/j.ygyno.2021.07.030. Epub 2021 Jul 24.

Joint IARC/NCI International Cancer Seminar Series Report: expert consensus on future directions for ovarian carcinoma research.

Carcinogenesis. 2021 Jun 21;42(6):785-793. doi: 10.1093/carcin/bgab043.

Choosing the right timing for interval debulking surgery and perioperative chemotherapy may improve the prognosis of advanced epithelial ovarian cancer: a retrospective study.

J Ovarian Res. 2021 Mar 27;14(1):49. doi: 10.1186/s13048-021-00801-4.

Neoadjuvant chemotherapy in advanced ovarian cancer: On what do we agree and disagree?

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Neoadjuvant chemotherapy in advanced ovarian cancer: On what do we agree and disagree?

作者信息

机构信息

出版信息

相似文献

引用本文的文献